New data on daraxonrasib monotherapy in second-line metastatic pancreatic ductal adenocarcinoma shows strong and lasting clinical effectiveness. The study observed a significant reduction in tumor size in 78% of patients, with a median progression-free survival of 8.4 months. These results highlight the potential of daraxonrasib as a treatment option for patients with this aggressive form of cancer.